Another Ranbaxy Drug Plant Fails FDA Test

Law360, New York (January 23, 2014, 7:24 PM ET) -- The U.S. Food and Drug Administration on Thursday barred drug products from a Ranbaxy Laboratories Inc. manufacturing plant in India from the U.S. market, the sixth company facility found to fail good manufacturing standards.

The FDA prohibited Ranbaxy's Toansa, India, site from manufacturing active pharmaceutical ingredients for FDA-regulated products after officials uncovered "significant" violations of U.S.-promulgated manufacturing practices meant to ensure drug safety.

Topping the list was Ranbaxy employees’ practice of retesting raw materials, intermediate drug products and finished APIs that failed to meet specifications until...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required